Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
- DOI
- 10.1016/s2665-9913(26)00315-2
- Published
- 2026 Nov 8
- Container
- The Lancet. Rheumatology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2665-9913-26-00315-2,
title = {Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.},
author = {Li Y and Shi G and Jiang G and Wei M and Liu Z and Wu Q and Nie Y and Wu R and Zhang L and Zhang H and Yang J and Liu Y and Song S and Wu X and Zheng Y and Sun L and Xie Q and Liang J and Li F and Li Z and BeSolve Investigators Group},
year = {2026},
journal = {The Lancet. Rheumatology},
doi = {10.1016/s2665-9913(26)00315-2},
url = {https://doi.org/10.1016/s2665-9913(26)00315-2}
}RIS
TY - JOUR TI - Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. AU - Li Y AU - Shi G AU - Jiang G AU - Wei M AU - Liu Z AU - Wu Q AU - Nie Y AU - Wu R AU - Zhang L AU - Zhang H AU - Yang J AU - Liu Y AU - Song S AU - Wu X AU - Zheng Y AU - Sun L AU - Xie Q AU - Liang J AU - Li F AU - Li Z AU - BeSolve Investigators Group PY - 2026 JO - The Lancet. Rheumatology DO - 10.1016/s2665-9913(26)00315-2 UR - https://doi.org/10.1016/s2665-9913(26)00315-2 ER -
APA
Y, L., G, S., G, J., M, W., Z, L., Q, W., Y, N., R, W., L, Z., H, Z., J, Y., Y, L., S, S., X, W., Y, Z., L, S., Q, X., J, L., F, L., Z, L., & Group, B. I. (2026). Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Rheumatology. https://doi.org/10.1016/s2665-9913(26)00315-2
Source records
- pubmed · retrieved 2026-11-10T14:04:53.803Z